Home › Lung Cancer › Oregon › Portland
Lung Cancer clinical trials in Portland, OR
26 studies for Lung Cancer are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Oregon Health & Science University (OHSU), Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi away
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
RecruitingPhase 1/2
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
RecruitingPhase 1
- PHN-012-001 Site, Portland
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
- Oregon Health and Science University ( Site 0052), Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Northwest Cancer Specialists, P.C., Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RecruitingPhase 2/3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Providence Portland Medical Center, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 3
- Oregon Health and Science University, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RecruitingPhase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RecruitingPhase 1/2
- Providence Portland Medical Center, Portland
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
RecruitingPhase 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- and 2 more
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- and 2 more
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- and 1 more
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
- Oregon Health Sciences University, Portland
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
RecruitingObservational study
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Portland
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RecruitingObservational study
- Oregon Health & Science University, Portland
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH37 studies
- Philadelphia, PA36 studies
Other studies in Portland
- Non-Small Cell Lung Cancer46 studies
- Cancer (all types)34 studies
- Prostate Cancer33 studies
- Breast Cancer33 studies
- Metastatic Cancer29 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Acute Myeloid Leukemia25 studies
- Endometrial Cancer24 studies
- Head and Neck Squamous Cell Carcinoma19 studies
- Pancreatic Cancer19 studies
- Heart Failure17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.